3093-66-1
3093-66-1 structure
- Name: 69-23-8 (free base)
- Chemical Name: fluphenazine dimaleate
- CAS Number: 3093-66-1
- Molecular Formula: C26H30F3N3O5S
- Molecular Weight: 553.59400
- Catalog: Signaling Pathways Anti-infection SARS-CoV
- Create Date: 2017-07-16 19:26:06
- Modify Date: 2025-08-25 08:44:53
-
Fluphenazine dimaleate is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dimaleate blocks neuronal voltage-gated sodium channels. Fluphenazine dimaleate acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dimaleate can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dimaleate can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2[1][2][3][4][6].
| Name | fluphenazine dimaleate |
|---|---|
| Synonyms |
fluphenazine dimaleate salt
MFCD00679032 |
| Description | Fluphenazine dimaleate is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dimaleate blocks neuronal voltage-gated sodium channels. Fluphenazine dimaleate acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dimaleate can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dimaleate can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2[1][2][3][4][6]. |
|---|---|
| Related Catalog | |
| Target |
Dopamine receptor, Sodium channels, SARS-CoV-2[1][2] |
| In Vivo | Fluphenazine (1 mg/kg; IG, treated from day 6 to day 15 of gestation) causes malformations in pregnant mice[5]. Fluphenazine (0.125-1 mg/kg; IP, single dosage) antagonizes Methylphenidate-induced stereotyped gnawing; inhibits significantly climbing behaviour[6]. Animal Model: Mature female Swiss-Webster mice[5] Dosage: 1 mg/kg Administration: IG, treated from day 6 to day 15 of gestation Result: Significantly reduced fetal weight and length, increased the incidence of incomplete ossification of sternebrae and skull bones. Animal Model: Mice (injected with 60 mg/kg Methylphenidate)[6] Dosage: 0.125, 0.25, 0.5, and 1 mg/kg Administration: IP, single dosage Result: Antagonized Methylphenidate-induced stereotyped gnawing; inhibited significantly climbing behaviour in mice at 0.0625-0.5 mg/kg, and at the dose of 1 mg/kg abolished this effect completely. |
| References |
| Molecular Formula | C26H30F3N3O5S |
|---|---|
| Molecular Weight | 553.59400 |
| Exact Mass | 553.18600 |
| PSA | 129.85000 |
| LogP | 3.96070 |
| Risk Phrases | 20/21/22-36/37/38 |
|---|---|
| Safety Phrases | 26-36 |
| RIDADR | UN 3249 |